AR029311A1 - UN MÉTODO PARA EL TRATAMIENTO DE LA VEJIGA URINARIA INESTABLE O HIPERACTIVA CON UNA FORMULACIoN DE LIBERACIoN CONTROLADA DE TOLTERODINA O COMPUESTOS RELACIONADOS; DICHA FORMULACIoN FARMACÉUTICA Y USO DE TOLTERODINA O DE COMPUESTOS RELACIONADOS. - Google Patents
UN MÉTODO PARA EL TRATAMIENTO DE LA VEJIGA URINARIA INESTABLE O HIPERACTIVA CON UNA FORMULACIoN DE LIBERACIoN CONTROLADA DE TOLTERODINA O COMPUESTOS RELACIONADOS; DICHA FORMULACIoN FARMACÉUTICA Y USO DE TOLTERODINA O DE COMPUESTOS RELACIONADOS.Info
- Publication number
- AR029311A1 AR029311A1 ARP990104280A ARP990104280A AR029311A1 AR 029311 A1 AR029311 A1 AR 029311A1 AR P990104280 A ARP990104280 A AR P990104280A AR P990104280 A ARP990104280 A AR P990104280A AR 029311 A1 AR029311 A1 AR 029311A1
- Authority
- AR
- Argentina
- Prior art keywords
- tolterodine
- related compounds
- unstable
- treatment
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Un método y formulacion para el tratamiento de la vejiga inestable o hiperactiva, en la cual se administra a un paciente una cantidad farmacéuticamente efectiva de tolterodina o un compuesto relacionado de tolterodina, o una sal farmacéuticamente aceptable de la misma, por medio de una formulacion de liberacion, controlada capaz de mantener un nivel sérico de actividad o actividades medias sustancialmente constante durante por lo menos 24 hs. Una formulacion farmacéutica que contiene tolterodina o un compuesto relacionado de tolterodina, o una sal de la misma farmacéuticamente aceptable, de liberacion controlada de tolterodina o un compuesto tolterodina relacionado, o una sal de la misma cuando se administra a pacientes. Preferentemente, la formulacion de liberacion controlada provee una media de índice de fluctuacion de dicho nivel sérico de actividad o actividades medias que no es mayor de aproximadamente 2,0 preferentemente no mayor de alrededor de 1,0 siendo definido dicho índice de fluctuacion, FI, como FI=(Cmax-Cmin)/AUCt/t, donde Cmax y Cmin son las concentraciones máxima y mínima, respectivamente, de la actividad o actividades medias, AUCt es el área bajo el perfil de la concentracion sérica y t es la longitud del intervalo de dosificacion. El uso de tolterodina o de un compuesto relacionado de tolterodina o una sal farmacéuticamente aceptable de la misma para la fabricacion de una formulacion terapéutica de liberacion controlada para el tratamiento de la vejiga inestable o hiperactiva.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9802864A SE9802864D0 (sv) | 1998-08-27 | 1998-08-27 | Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder |
| SE9803871A SE9803871D0 (sv) | 1998-11-11 | 1998-11-11 | Therapeutic method and formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR029311A1 true AR029311A1 (es) | 2003-06-25 |
Family
ID=26663376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990104280A AR029311A1 (es) | 1998-08-27 | 1999-08-26 | UN MÉTODO PARA EL TRATAMIENTO DE LA VEJIGA URINARIA INESTABLE O HIPERACTIVA CON UNA FORMULACIoN DE LIBERACIoN CONTROLADA DE TOLTERODINA O COMPUESTOS RELACIONADOS; DICHA FORMULACIoN FARMACÉUTICA Y USO DE TOLTERODINA O DE COMPUESTOS RELACIONADOS. |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US6770295B1 (es) |
| EP (2) | EP2153825A1 (es) |
| CN (1) | CN1239152C (es) |
| AP (1) | AP1529A (es) |
| AR (1) | AR029311A1 (es) |
| AT (1) | ATE487471T1 (es) |
| AU (1) | AU745190B2 (es) |
| BG (1) | BG65168B1 (es) |
| CA (1) | CA2311755C (es) |
| CY (1) | CY1111088T1 (es) |
| CZ (1) | CZ302630B6 (es) |
| DE (1) | DE69942928D1 (es) |
| DK (1) | DK1039882T3 (es) |
| EA (1) | EA002720B1 (es) |
| GE (1) | GEP20043354B (es) |
| HK (1) | HK1034664A1 (es) |
| HU (1) | HUP0100437A3 (es) |
| ID (1) | ID25824A (es) |
| IL (1) | IL136294A (es) |
| IS (1) | IS2976B (es) |
| ME (1) | ME00850B (es) |
| MY (1) | MY127946A (es) |
| NO (1) | NO329830B1 (es) |
| NZ (1) | NZ504618A (es) |
| OA (1) | OA11636A (es) |
| PT (1) | PT1039882E (es) |
| SI (1) | SI1039882T1 (es) |
| SK (1) | SK287111B6 (es) |
| TR (1) | TR200001998T1 (es) |
| UA (1) | UA72882C2 (es) |
| WO (1) | WO2000012069A1 (es) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0957073A1 (en) * | 1998-05-12 | 1999-11-17 | Schwarz Pharma Ag | Novel derivatives of 3,3-diphenylpropylamines |
| DE19922662C1 (de) * | 1999-05-18 | 2000-12-28 | Sanol Arznei Schwarz Gmbh | Transdermales therapeutisches System (TTS) Tolterodin enthaltend |
| DE19932651A1 (de) * | 1999-07-13 | 2001-01-18 | Hexal Ag | Transdermales therapeutisches System zur Anwendung von Tolterodin |
| CZ304671B6 (cs) | 1999-11-11 | 2014-08-27 | Pharmacia Ab | Farmaceutický prostředek obsahující tolterodin a jeho použití |
| DE10149674A1 (de) | 2001-10-09 | 2003-04-24 | Apogepha Arzneimittel Gmbh | Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung |
| US20030185882A1 (en) | 2001-11-06 | 2003-10-02 | Vergez Juan A. | Pharmaceutical compositions containing oxybutynin |
| US8329217B2 (en) | 2001-11-06 | 2012-12-11 | Osmotica Kereskedelmi Es Szolgaltato Kft | Dual controlled release dosage form |
| EP1441707A1 (en) * | 2001-11-09 | 2004-08-04 | Pharmacia AB | Anti-muscarinic agent and estrogen-agonist for treating unstable or overactive bladder |
| US6773421B2 (en) | 2001-12-14 | 2004-08-10 | Kimberly-Clark Worlwide, Inc. | Combination for managing the involuntary loss of bladder control |
| EP1424079A1 (en) * | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine |
| ES2341240T3 (es) * | 2002-12-13 | 2010-06-17 | Warner-Lambert Company Llc | Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior. |
| ES2324712T5 (es) † | 2003-01-22 | 2012-06-08 | Pfizer Health Ab | Dosis reducida de tolterodina para tratar trastornos urinarios |
| DE10315917A1 (de) * | 2003-04-08 | 2004-11-18 | Schwarz Pharma Ag | Hochreine Basen von 3,3-Diphenylpropylaminmonoestern |
| EP1635795A1 (en) * | 2003-05-30 | 2006-03-22 | Ranbaxy Laboratories, Ltd. | Controlled release pharmaceutical compositions of tolterodine and processes for their preparation |
| DK2210605T3 (en) | 2003-11-04 | 2017-05-22 | Tcd Royalty Sub Llc | Daily single dose doses of trospium. |
| JP4771956B2 (ja) | 2003-11-04 | 2011-09-14 | スパーナス ファーマシューティカルズ インコーポレイテッド | バイオアベイラビリティーエンハンサを含む第四級アンモニウム化合物の組成物 |
| WO2005105036A1 (en) * | 2004-04-28 | 2005-11-10 | Natco Pharma Limited | Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation |
| EP1629834A1 (en) † | 2004-08-27 | 2006-03-01 | KRKA, D.D., Novo Mesto | Sustained release pharmaceutical composition of tolterodine |
| US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
| PL1874282T3 (pl) | 2005-04-06 | 2011-04-29 | Adamas Pharmaceuticals Inc | Sposoby i kompozycje do leczenia zaburzeń OUN |
| CN1330297C (zh) * | 2005-07-04 | 2007-08-08 | 宛六一 | 酒石酸托特罗定软胶囊及其制备方法 |
| KR20070012205A (ko) * | 2005-07-22 | 2007-01-25 | 주식회사종근당 | 경시 안정성을 갖는 톨테로딘을 함유하는 제어방출형 펠렛 |
| CA2882048C (en) | 2006-02-03 | 2020-03-24 | Proventiv Therapeutics, Llc | Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3 |
| EP2015735A1 (en) * | 2006-04-21 | 2009-01-21 | Synthon B.V. | Tolterodine beads |
| PL2679228T3 (pl) | 2006-06-21 | 2018-07-31 | Opko Ireland Global Holdings, Ltd. | Terapia z użyciem środka do uzupełniania witaminy D i środka do zastępowania hormonami witaminy D |
| WO2008134523A1 (en) | 2007-04-25 | 2008-11-06 | Proventiv Therapeutics, Llc | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease |
| EP3542792B1 (en) | 2007-04-25 | 2023-06-28 | EirGen Pharma Ltd. | Controlled release 25-hydroxyvitamin d |
| ES2403107T3 (es) | 2007-04-25 | 2013-05-14 | Cytochroma Inc. | Método de tratamiento de insuficiencia y deficiencia de vitamina D |
| EP2173329A1 (en) * | 2007-07-03 | 2010-04-14 | Synthon B.V. | Tolterodine bead |
| US8486452B2 (en) * | 2007-07-20 | 2013-07-16 | Mylan Pharmaceuticals Inc. | Stabilized tolterodine tartrate formulations |
| WO2009019599A2 (en) | 2007-08-08 | 2009-02-12 | Themis Laboratories Private Limited | Extended release compositions comprising tolterodine |
| US20090192228A1 (en) * | 2008-01-28 | 2009-07-30 | Actavis Group Ptc Ehf | Controlled-Release Tolterodine Compositions and Methods |
| US20090214665A1 (en) * | 2008-02-26 | 2009-08-27 | Lai Felix S | Controlled Release Muscarinic Receptor Antagonist Formulation |
| US8962239B2 (en) | 2008-04-02 | 2015-02-24 | Opko Renal, Llc | Methods useful for vitamin D deficiency and related disorders |
| TWI630208B (zh) | 2008-12-08 | 2018-07-21 | 歐陸斯迪公司 | 二氫羥戊甲嗎啡 |
| KR101004205B1 (ko) | 2008-12-17 | 2010-12-24 | 동아제약주식회사 | 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물 |
| WO2011095388A1 (en) | 2010-02-04 | 2011-08-11 | Synthon Bv | Tolterodine bead |
| KR101746204B1 (ko) * | 2010-02-18 | 2017-06-13 | 에스케이케미칼주식회사 | 피부 투과가 개선된 톨테로딘의 경피 투여용 조성물 |
| HUE048464T2 (hu) | 2010-03-29 | 2020-07-28 | Opko Ireland Global Holdings Ltd | Módszerek és készítmények mellékpajzsmirigy szintjének csökkentésére |
| EP2563123B1 (en) | 2010-04-30 | 2018-04-25 | Merck Sharp & Dohme Corp. | Novel beta 3 adrenergic receptor agonists |
| DE102010024105A1 (de) * | 2010-06-17 | 2011-12-22 | Grünenthal GmbH | Transdermale Verabreichung von Memantin |
| EP2601944B1 (en) * | 2010-08-03 | 2021-02-17 | Hisamitsu Pharmaceutical Co., Inc. | Transdermal patch and method for augmenting adhesive strength thereof |
| KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| GB201309654D0 (en) | 2013-05-30 | 2013-07-17 | Euro Celtique Sa | Method |
| CA2957240A1 (en) | 2014-08-07 | 2016-02-11 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin d |
| JP7032322B2 (ja) | 2016-03-28 | 2022-03-08 | オプコ アイルランド グローバル ホールディングス リミテッド | ビタミンｄ治療法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3598123A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| SE8800207D0 (sv) | 1988-01-22 | 1988-01-22 | Kabivitrum Ab | Nya aminer, deras anvendning och framstellning |
| US5382600A (en) * | 1988-01-22 | 1995-01-17 | Pharmacia Aktiebolag | 3,3-diphenylpropylamines and pharmaceutical compositions thereof |
| MX9302812A (es) * | 1992-05-13 | 1993-11-01 | Alza Corp | Administracion transdermica de oxibutinina. |
| SE9203318D0 (sv) | 1992-11-06 | 1992-11-06 | Kabi Pharmacia Ab | Novel 3,3-diphenylpropylamines, their use and preparation |
| TW344661B (en) * | 1993-11-24 | 1998-11-11 | Lilly Co Eli | Pharmaceutical composition for treatment of incontinence |
| AU7994694A (en) | 1994-10-21 | 1996-05-15 | Leiras Oy | Controlled release oral delivery system containing oxybutynin |
| US5677346A (en) * | 1995-01-31 | 1997-10-14 | Sepracor, Inc. | Treating urinary incontinence using (S)-desethyloxybutynin |
| AU728395B2 (en) | 1996-07-19 | 2001-01-11 | Gunnar Aberg | S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders |
| KR20010029519A (ko) | 1996-09-19 | 2001-04-06 | 이곤 이 버그 | 요실금 치료 방법 |
-
1999
- 1999-08-26 EA EA200000468A patent/EA002720B1/ru not_active IP Right Cessation
- 1999-08-26 NZ NZ504618A patent/NZ504618A/xx not_active IP Right Cessation
- 1999-08-26 HU HU0100437A patent/HUP0100437A3/hu unknown
- 1999-08-26 PT PT99946521T patent/PT1039882E/pt unknown
- 1999-08-26 TR TR2000/01998T patent/TR200001998T1/xx unknown
- 1999-08-26 GE GE3951A patent/GEP20043354B/en unknown
- 1999-08-26 US US09/582,498 patent/US6770295B1/en not_active Expired - Lifetime
- 1999-08-26 EP EP09173927A patent/EP2153825A1/en not_active Withdrawn
- 1999-08-26 DK DK99946521.4T patent/DK1039882T3/da active
- 1999-08-26 EP EP99946521A patent/EP1039882B1/en not_active Revoked
- 1999-08-26 AR ARP990104280A patent/AR029311A1/es not_active Application Discontinuation
- 1999-08-26 CZ CZ20001924A patent/CZ302630B6/cs not_active IP Right Cessation
- 1999-08-26 SK SK749-2000A patent/SK287111B6/sk not_active IP Right Cessation
- 1999-08-26 SI SI9931050T patent/SI1039882T1/sl unknown
- 1999-08-26 ID IDP20001006A patent/ID25824A/id unknown
- 1999-08-26 UA UA2000052950A patent/UA72882C2/uk unknown
- 1999-08-26 IL IL13629499A patent/IL136294A/en unknown
- 1999-08-26 AP APAP/P/2000/001823A patent/AP1529A/en active
- 1999-08-26 ME MEP-2001-331A patent/ME00850B/me unknown
- 1999-08-26 OA OA1200000309A patent/OA11636A/en unknown
- 1999-08-26 WO PCT/SE1999/001463 patent/WO2000012069A1/en active Application Filing
- 1999-08-26 CA CA2311755A patent/CA2311755C/en not_active Expired - Lifetime
- 1999-08-26 AT AT99946521T patent/ATE487471T1/de active
- 1999-08-26 CN CNB99801916XA patent/CN1239152C/zh not_active Expired - Lifetime
- 1999-08-26 MY MYPI99003665A patent/MY127946A/en unknown
- 1999-08-26 DE DE69942928T patent/DE69942928D1/de not_active Expired - Lifetime
- 1999-08-26 AU AU58918/99A patent/AU745190B2/en not_active Expired
-
2000
- 2000-05-26 BG BG104476A patent/BG65168B1/bg unknown
- 2000-06-09 NO NO20002977A patent/NO329830B1/no not_active IP Right Cessation
- 2000-06-15 IS IS5537A patent/IS2976B/is unknown
-
2001
- 2001-07-12 HK HK01104868A patent/HK1034664A1/xx not_active IP Right Cessation
-
2010
- 2010-11-17 CY CY20101101027T patent/CY1111088T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR029311A1 (es) | UN MÉTODO PARA EL TRATAMIENTO DE LA VEJIGA URINARIA INESTABLE O HIPERACTIVA CON UNA FORMULACIoN DE LIBERACIoN CONTROLADA DE TOLTERODINA O COMPUESTOS RELACIONADOS; DICHA FORMULACIoN FARMACÉUTICA Y USO DE TOLTERODINA O DE COMPUESTOS RELACIONADOS. | |
| DK0804191T3 (da) | Anvendelse af inhibitorer for den fra blodplader hidhørende vækstfaktor-receptor til fremstilling af et lægmiddel til behan | |
| AR035863A1 (es) | Ligandos receptores de melanocortina | |
| MX9204881A (es) | Composicion farmaceutica que comprende moleculas activas, receptoras de calcio. | |
| BR0108977A (pt) | Compostos azacìclicos para uso no tratamento de doenças relaciondas com serotonina | |
| RU2002132882A (ru) | Кожные композиции, содержащие кофермент q в качестве активного ингредиента | |
| JP2005520778A (ja) | 鎮痛薬として使用するための６−ヒドロキシ−オキシモルホンの非経口投与 | |
| RU2005135958A (ru) | Способ лечения с использованием лекарственных форм, содержащих фармацевтические композиции 5, 8, 14-триазатетрацикло[10.3.1.02,11.04,9]-гексадека-2( 11 ), 3,5,7,9-пентаена | |
| DE3575927D1 (de) | Purinderivate, verfahren zu ihrer herstellung und pharmazeutische zubereitung. | |
| RU2012110592A (ru) | Соединения и способ снижения мочевой кислоты | |
| JPH08501538A (ja) | ホスホジェステラーゼ ▲ｉｖ▼のインヒビターの新規使用 | |
| DE50211566D1 (de) | Kombination ausgewählter opioide mit muscarin-antagonisten zur therapie der harninkontinenz | |
| NO980793L (no) | Anvendelse av aminoadamantanforbindelse som immunregulatorer | |
| KR950031085A (ko) | 표피증식 질환 치료용 의약 조성물 | |
| ES2058148T3 (es) | N-benzopiranil-lactamas sustituidas con alquilo, procedimiento para su preparacion, su empleo, asi como preparados farmaceuticos a base de estos compuestos. | |
| DK0488928T3 (da) | Pharmaceutiske formuleringer, der indeholder en blanding af højere, primære, alifatiske alkoholer, til behandling af hyperc | |
| RU95113499A (ru) | Способ повышения мочеотделения у человека, способ снижения уровней холестерина и липопротеинов низкой плотности, применение (+) доксазозина | |
| KR910018348A (ko) | 술포닐아미노치환 비시클로환계 히드록삼산 유도체 | |
| ES2036560T3 (es) | Un metodo para preparar una composicion sinergicamente activa para el tratamiento de hipertension. | |
| CA2454544A1 (en) | Optic nerve protecting agents containing .alpha.1 receptor blocker as active ingredient | |
| Koulu et al. | Skin photosensitizing and Langerhans cell depleting activity of topical (bath) PUVA therapy: comparison of trimethylpsoralen and 8-methoxypsoralen | |
| US20110196035A1 (en) | Temporally-Controlled Treatment of Joint Disease | |
| AR033779A1 (es) | Compuestos utiles en la enfermedad de reflujo | |
| KR880004810A (ko) | 소화성 궤양 치료제 | |
| RU2003113987A (ru) | Способ лечения и профилактики заболеваний воздействием на биологически активные точки и зоны |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |